PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
1.740
-0.090 (-4.92%)
Nov 4, 2024, 4:00 PM EST - Market closed
PharmaCyte Biotech Ratios and Metrics
Market cap in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Nov '24 Nov 4, 2024 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 | Apr '20 Apr 30, 2020 |
| Market Capitalization | 13 | 18 | 51 | 48 | 42 | 36 | |
| Market Cap Growth | -29.04% | -64.82% | 5.50% | 14.27% | 16.41% | -21.44% | |
| Enterprise Value | -14 | -20 | -22 | -38 | 39 | 36 | |
| Last Close Price | 1.74 | 2.12 | 2.92 | 2.33 | 26.57 | 36.75 | |
| PE Ratio | 3.25 | -1.18 | -13.19 | -8.53 | -10.84 | -8.68 | |
| PB Ratio | 0.28 | 0.40 | 0.70 | 0.54 | 6.33 | 7.13 | |
| P/FCF Ratio | -5.78 | -8.33 | -13.43 | -11.73 | -12.69 | -15.52 | |
| P/OCF Ratio | -5.78 | -8.33 | -13.43 | -11.73 | -12.69 | -15.52 | |
| EV/EBIT Ratio | 3.82 | 3.14 | 3.36 | 8.73 | -10.83 | -9.45 | |
| EV/FCF Ratio | 7.61 | 9.52 | 5.72 | 9.32 | -11.78 | -15.47 | |
| Debt / Equity Ratio | - | - | - | - | 0.01 | 0.04 | |
| Debt / FCF Ratio | - | - | - | - | -0.02 | -0.08 | |
| Quick Ratio | 4.37 | 31.60 | 115.99 | 121.24 | 3.04 | 0.87 | |
| Current Ratio | 4.40 | 31.76 | 116.18 | 121.38 | 3.14 | 1.01 | |
| Return on Equity (ROE) | 47.88% | 0.57% | -5.31% | -8.78% | -60.35% | -75.57% | |
| Return on Assets (ROA) | -4.76% | -6.12% | -4.92% | -5.60% | -33.37% | -40.03% | |
| Return on Capital (ROIC) | -6.35% | -6.90% | -4.96% | -5.68% | -37.72% | -46.36% | |
| Earnings Yield | 33.64% | 1.86% | -8.47% | -8.78% | -8.40% | -10.54% | |
| FCF Yield | -21.46% | -12.01% | -7.45% | -8.53% | -7.88% | -6.44% | |
| Buyback Yield / Dilution | 51.83% | 50.84% | -25.56% | -971.73% | -60.24% | -23.23% | |
| Total Shareholder Return | 51.83% | 50.84% | -25.56% | -971.73% | -60.24% | -23.23% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.